Kornimate/medical-research-clean huggingface dataset:
quality of life after surgery for pancreatic carcinoma

Conditions: Patients Suspected for a Pancreatic (Pre-)Malignancy

Summary: pancreatic cancer has a high mortality rate. patients with an intended curative resection show a median survival of 17-23 months. therefore, quality of life is very important in this patient group. in this study, the effect of pancreatic surgery on quality of life is measured.


Eligibility criteria:
inclusion criteria: * patients with a suspected pancreatic malignancy * eligible for surgery with curative intent * being able to complete questionnaires in dutch * age \>=18 years exclusion criteria: * none
incisional hernia after midline versus transverse extraction incision in laparoscopic colectomy

Conditions: Laparoscopic Colectomy

Summary: incisional hernia (ih) is a common complication of midline laparotomy. despite the hope that laparoscopic colon resection would result in fewer incisional hernias, prospective studies demonstrate a similar incidence to open surgery. observational studies suggest that the rate of incisional hernia after laparoscopic colon resection may be reduced with the use of a transverse compared to a midline extraction incision. however, no randomized trails are available, and a midline extraction incision for hemicolectomy remains the standard current approach. the investigators hypothesize that the use of a lower abdominal transverse muscle splitting incision for specimen extraction in laparoscopic colon surgery will result in fewer incisional hernias compared to a midline periumbilical extraction incision.


Eligibility criteria:
inclusion criteria: * scheduled laparoscopic partial colectomy where an abdominal extraction incision is planned exclusion criteria: * previous laparotomy * rectal resection or anastamosis * planned pfannenstiel extraction incision * single site surgery * planned or performed stoma * bmi \>35 kg/m2 * asa 4-5

Keywords: laparoscopy colon resection incisional hernia
artemether-lumefantrine effectiveness in guinea-bissau

Conditions: Malaria

Summary: the routine treatment of children with antimalarials will be monitored. children with a positive malaria film and/or a positive rapid diagnostic test (rdt) will be included in a follow-up study. the genetic basis of the parasites for developing resistance will be examined. in case of reappearance of parasites the child will be re-treated following the guidelines of the national malaria programme.

children from the bandim area in bissau who are seeking medical advice and who are recommended treatment for malaria in accordance with the current routines will be included as follows: all children getting the clinical diagnosis of malaria will be registered and basic information collected. of theses, children fulfilling the inclusion criteria will be included in a follow-up study. the children included in the follow-up part of the study will be visited on day 7, day 14, day 21, day 28, day 35 and day 42. at each visit the condition of the child will be evaluated, a questionnaire will be filled in and a malaria film and approximately 100 µl blood on filter-paper (for pcr analysis in case of re-parasitaemia) will be taken. furthermore, on day seven 100 μl blood on filter-paper will be taken for drug-analysis. children with parasitaemia detected by only one of the following methods will be excluded from the final analyses of the effectiveness: 1) malaria film, 2) rdt, and 3) pcr. if the parents do not ensure that the children get the correct medication resulting in a high rate of recrudescence and/or a low drug-concentration on day seven the policy of the national malaria programme should be re-evaluated. if the health staff do not follow the guidelines of the national malaria programme the reasons why should be elucidated in order to ensure a better adherence.

Eligibility criteria:
inclusion criteria: * prescribed an anti-malarial at the bandim health centre * having p. falciparum parasites in a thick film and/or a positive rdt * the bandim address is known (to enable follow up). exclusion criteria: * children where the parents do not accept to participate in the study. * signs of severe malaria such as convulsion or severe anemia

Keywords: malaria children guinea-bissau artemether lumefantrine effectiveness
effectiveness of smecta in combination with oral rehydration in the treatment of acute watery diarrhoea in infants and children

Conditions: Diarrhoea

Summary: the purpose of this study is to evaluate the effectiveness of smecta at decreasing stool weight, when compared to placebo, in the treatment of acute diarrhoea in children.


Eligibility criteria:
inclusion criteria: * male * acute watery diarrhoea defined as at least 3 watery stools per 24 hours * duration of watery diarrhoea of less than 72 hours and with at least 1 watery stool for the last 12 hours * dehydration signs requiring oral rehydration according to current who guidelines exclusion criteria: * severe dehydration that needs iv therapy * presence of gross blood in stools * fever \>39 degrees celsius
effects of preservation rhinoplasty nasal valve angle and area

Conditions: Nasal Obstruction, Bilateral

Summary: the study planned to compare the internal nasal valve angle measurements of patients who underwent preservation rhinoplasty before and after surgery.

nasal congestion is one of the most common complaints in otorhinolaryngology medicine. one of the most common causes of this is the collapse or blockage of the internal nasal valve (inv). the internal nasal valve is the narrowest part of the airway and creates the greatest resistance to airflow. its most important function is to regulate the inspiratory airflow. it is determined by the angle formed between the caudal part of the upper lateral cartilage and the nasal septal cartilage. this angle normally varies between 9-15 degrees. the tip of the inferior turbinate and the tissues surrounding the piriform aperture may affect this area. when this angle is less than 9 degrees, the valve collapses in inspiration. the internal nasal valve region should be evaluated in every patient complaining of nasal congestion. the investigators planned to radiologically examine the improvement in the internal nasal valve angle of the patients we operated on.

Eligibility criteria:
inclusion criteria: * preservation rhinoseptoplasty exclusion criteria: * absence of nasal obstruction * previous nasosinusal surgery * cranio-facial anomalies * presence of nasosinusal tumors
identification of hypoxic brain tissues by f-miso pet in acute ischemic stroke

Conditions: Ischemic Stroke

Summary: this study is a french multicenter prospective study including 5 stroke units with available mri and f-miso pet for patients with acute ischemic stroke. background and purpose: 18f-fluoromisonidazole (fmiso) pet has been used to identify hypoxic tissues in animals and stroke patients. while mri has become the gold standard acute stroke imaging, no published study has compared fmiso pet and mri. the aim of this prospective study is to identify hypoxic tissues in 40 patients with acute ischemic stroke with f-miso pet and to compare the location and the outcome of these hypoxic cells with mri datas (weighted diffusion and flair) and to clinical outcome.

40 prospective patients (aged 18 to 85 years) will be included in the first 36 hours after ischemic stroke onset. the study period will be 2 years. included patients will have f-miso pet followed by brain mri (mri-1)(diffusion, flair, perfusion, tof) as soon as possible after stroke onset (less than 36 hours). a second brain mri (mri-2) will be performed on day 7. the aim of the study is to locate hypoxic tissues and to compare with ischemic tissues defined by diffusion and flair mri sequences, with mri evolution, and with clinical status at day 7 and day 90. inclusion criterias * patients aged 18-85 years with encephalic brain ischemic stroke, * defined stroke onset, * nihss 5 to 20, * f-miso pet and mri available \<36 hours after stroke onset,

Eligibility criteria:
inclusion criteria: * patients aged 18-85 years with encephalic brain ischemic stroke, * defined stroke onset, * nihss 5 to 20, * f-miso pet and mri available \<36 hours after stroke onset, * written consent signed by patient or family exclusion criteria: * contraindication to mri * comatous status * 5 \ 20 * non ischemic stroke * brainstem stroke

Keywords: ischemic stroke hypoxic tissues f-miso uptake magnetic resonance imaging f-miso positon emission tomography
pentoxifylline for vascular calcification in kidney disease

Conditions: Chronic Kidney Disease; Vascular Calcification; Kidney Failure, Chronic

Summary: this study is research to find out if the drug pentoxifylline can help prevent or lessen the problem of blood vessel hardening (vascular calcification) in people with chronic kidney disease (ckd). people with ckd are at higher risk for heart problems and blood vessel hardening. vascular calcification happens when calcium builds up in the blood vessels, making them stiff. pentoxifylline is a drug that might have helpful effects that could reduce this hardening. in this study, some ckd patients will receive pentoxifylline in addition to their usual medications, while others will only receive their usual medications. the researchers will then compare the amount of vascular calcification in both groups over 6 months to see if pentoxifylline makes a difference. the goal is to learn if pentoxifylline could be a new way to protect the blood vessels of people with chronic kidney disease.


Eligibility criteria:
inclusion criteria: * estimated glomerular filtration rate (egfr) less than 60 ml/min/1.73 m² and greater than or equal to 15 ml/min/1.73 m². * adult patients, age 18 years or older. * diagnosis of chronic kidney disease (ckd). * willing and able to provide informed consent. exclusion criteria: * patients currently undergoing regular hemodialysis. * history of kidney transplantation or are kidney transplant recipients. * pregnant females. * patients with a history of coronary artery bypass grafting (cabg). * known allergy or contraindication to pentoxifylline. * inability to comply with study procedures or attend follow-up visits.

Keywords: kidney failure, chronic vascular calcification pentoxifylline ckd
impact of a high saturated fat diet on fasted systemic and white adipose tissue inflammatory responses

Conditions: Inflammation; Obesity; Inflammatory Response; Cardiovascular Diseases

Summary: this study will investigate the effect of a 7-day westernised high-fat (65% of kilocalories), high-calorie (150% of requirements) diet on markers of inflammation in the blood and white adipose tissue. participants will firstly complete a 3-day weight maintenance phase (days 1-3) before completing a 7-day high fat diet intervention (days 4-10). on days 4 and 11 participants will complete a laboratory visit where anthropometric measurements, blood and adipose samples will be collected. the investigators hypothesise that consuming a high-fat, high-calorie diet for 7 days will alter the inflammatory responses in white adipose tissue and will induce metabolic endotoxaemia / systemic inflammation.


Eligibility criteria:
inclusion criteria: * 18-40 years * bmi = 21.0-29.9 kg/m2 * male or female * physically active (\> 3 x 30 min moderate exercise per week) * healthy * no cardiometabolic (e.g. heart disease, high blood pressure, type 2 diabetes) or inflammatory illness exclusion criteria: * inactive (\< 3 x 30 min moderate exercise per week) * smoker * women who are pregnant or lactating * medication/supplements known to interfere with study outcomes or prescribed antibiotics within the last 3 months * unstable weight history (≥3kg loss or gain in the previous 3 months) * an allergy to lidocaine * food allergies (e.g. gluten, dairy) and intolerances (e.g. lactose) which could impede compliance to the diet * vegetarian/ vegan (as the high-fat diet is based on animal fats) * consumption of probiotics yogurts during or within the four weeks prior to the start of the study (e.g. actimel, activia, yakult, yeo valley) * alcohol consumption \>28 units per week for a man (i.e. not more than 14 pints of beer or 28 small glasses of wine) or \>21 units per week for a woman (i.e. more than 10 and a half pints of beer or 21 small glasses of wine) * any other unusual medical history or diet and lifestyle habits or practices that would preclude volunteers from participating in a dietary intervention or metabolic study * restrained eaters (determined by three factor eating questionnaire)
enhancing medical compliance and health-related quality of life of patients with epilepsy

Conditions: Epilepsy

Summary: improving medical compliance and health-related quality of life (hrqol) among people with epilepsy (pwe) has become the focus of various treatment programs and behavioral interventions which continue to be challenging to both patients and health care professionals. in order to design an effective intervention on the management of epilepsy, the drug management of epilepsy by community health workers was evaluated.


Eligibility criteria:
inclusion criteria: * eligible participants must have a definitive diagnosis of epilepsy for at least 6 months, based on the clinical judgement of the investigators. epilepsy is defined by two or more unprovoked seizures. clinical history, electroencephalography, and imaging data are all instrumental in rendering a formal decision. the seizure type, frequency, or severity are not criteria for exclusion, although this information will be recorded. * patients must have a seizure frequency of at least two seizures in a 6 month period of time. * patients must be on at least one anti-epileptic medication. * patients must be able to report seizure frequency with either a paper or electronic diary. * patients must be able to read and understand either english or hindi. * patients must be able to complete questionnaires and provide informed consent to this study. exclusion criteria: * a diagnosis of psychogenic nonepileptic seizures * severe depression, anxiety, or psychosis * recent problem with substance abuse.
safety and immunogenicity study of hiv-mag vaccine +/- il-12 and ad35-grin/env in hiv-uninfected volunteers

Conditions: HIV Infections

Summary: the purpose of this study is to evaluate the safety, tolerability and immunogenicity of multiantigen hiv (hiv-mag) plasmid dna (pdna) vaccine co-administered with recombinant human il-12 pdna (genevax® il-12) followed or preceded by recombinant ad35-grin/env hiv vaccine in low-risk for hiv-uninfected healthy adults.

the study is a randomized, double-blind placebo-controlled trial assessing the safety and tolerability of hiv-mag with or without co-administered genevax® il-12 given intramuscularly by in vivo electroporation (im/ep) using the ichor medical systems trigrid delivery system (tds-im) followed by ad35-grin/env in each of four different regimens. an additional group will evaluate the safety and tolerability of ad35-grin/env followed by hiv-mag with co-administered genevax® il-12 given intramuscularly by in vivo electroporation (im/ep) using the ichor medical systems trigrid delivery system (tds-im). volunteers will be screened up to 42 days before the 1st vaccination and will be followed for 12 months after the first vaccine administration. it is anticipated that it will take approximately 3 months to enrol the study. approximately 75 volunteers (60 vaccine/15 placebo recipients) will be included in the study.

Eligibility criteria:
inclusion criteria: * healthy male or female adults, * 18 to 50 years of age (21 to 50 years of age for volunteers in rwanda), * who do not report high-risk behaviour for hiv infection, * who are available for the duration of the trial, * who are willing to undergo hiv testing, * use an effective method of contraception, and * who, in the opinion of the principal investigator or designee, understand the study and who provide written informed consent. principal exclusion criteria: * confirmed hiv infection, * pregnancy and lactation, * significant acute or chronic disease, * clinically significant laboratory abnormalities, * recent vaccination or receipt of a blood product, * previous receipt of an hiv vaccine, and * previous severe local or systemic reactions to vaccination or history of severe allergic reactions.

Keywords: hiv aids hiv vaccine hiv prevention
a trial of 18-22mg/kg/d ursodeoxycholic in refractory primary biliary cholangitis

Conditions: Primary Biliary Cholangitis

Summary: this study evaluates the effect of 18-22mg/kg/d ursodeoxycholic in refractory primary biliary cholangitis


Eligibility criteria:
inclusion criteria: * patients diagnosed with primary biliary cholangitis * treated with ursodeoxycholic acid in west china hospital for at least 6 month and suboptimal response to ursodeoxycholic acid exclusion criteria: * autoimmune hepatitis * primary sclerosing cholangitis

Keywords: ursodeoxycholic acid
tranilast vs. steroids to prevent esophageal stricture (tapes) after endoscopic resection for superficial neoplasms

Conditions: Esophageal Stricture; Esophageal Neoplasms

Summary: the goal of this clinical trial is to learn if tranilast works to prevent esophageal stricture after circumferential endoscopic submucosal dissection (cesd) in adults. it will also help us learn more about the safety of tranilast. the main questions it aims to answer are: 1. does tranilast reduce the occurence of esophageal stricture in participants after cesd? 2. what medical problems do participants have when taking tranilast. researchers will compare tranilast to prednisone (a steroid used in clinical practice with potential defects) to see if tranilast works well to prevent esophageal stricture. participants will: 1. take tranilast or prednisone every day for 8 weeks. 2. attend visit (at clinic or phone) once every 2 weeks for checkups and tests until 16 weeks. 3. keep a diary of their symptoms and let researchers know during the 16 weeks follow up.

esophageal strictures are a frequent complication after cesd for superficial esophageal tumors, which significantly affects patients' quality of life and often necessitates repeated endoscopic interventions. currently, steroids are widely used to prevent post-cesd strictures, but their side effects, including increased risks of infection and delayed wound healing, limit their use. tranilast, an anti-inflammatory and antifibrotic agent, has shown potential in preventing fibrosis in preclinical studies, but its clinical efficacy in preventing esophageal stricture after cesd remains unclear. this randomized, parallel, single-blinded non-inferiority trial aims to compare the efficacy and safety of tranilast with steroids in preventing esophageal strictures post-cesd. the primary outcome is the incidence of esophageal stricture within 16 weeks after cesd. it is a composite outcome defined as the inability to pass a standard endoscope (diameter 10.8 mm) through the stricture site at 16 weeks, or the presence of clinical symptoms of esophageal stricture (such as difficulty swallowing solid food) occurring before the endoscopic assessment at 16 weeks. secondary outcomes include drug-related side effects, postoperative adverse events, and quality of life scores. this study will provide valuable insights into whether tranilast can serve as an effective and safer alternative to corticosteroids in this setting.

Eligibility criteria:
inclusion criteria: 1. age\>18 and proficient in mandarin. 2. underwent cesd treatment for superficial esophageal neoplasms. 3. agree to sign an informed consent form. exclusion criteria: 1. allergic to tranilast. 2. with severe comorbid conditions. 3. pregnant or breastfeeding.

Keywords: tranilast esophageal neoplasms steroids esophageal stricture circumferential endoscopic submucosal dissection
intratracheal vitamin a administration with surfactant for newborn respiratory distress syndrome

Conditions: RDS; Infant, Newborn; Vitamin A; Surfactant

Summary: to research the effect of vitamin a to newborn respiratory distress syndrome by intratracheal administration with surfactant.

chronic lung disease (cld) of prematurity is the major cause of long-term disability of extremely lbw (elbw) premature infants, and it is the most cost consumptive disease in neonatal intensive care unit graduates. vitamin a plays an important role in the development of premature lung. nevertheless, premature infants are prone to vitamin a deficiency. oral supplementation of vitamin a does not alter the incidence of cld in elbw infants. intramuscular administration of vitamin a reduced the incidence of cld. the treatment is considered painful and this way is not routinely practiced. vitamin a is systemically bioavailable after intratracheal administration with surfactant in an animal model of newborn respiratory distress.

Eligibility criteria:
inclusion criteria: * 1.newborn infants with birth weight \>500 gm. * 2.gestational age \>24 completed weeks. * 3.intention to manage the infant with non-invasive respiratory support (i.e. no endotracheal tube), where either: 1) the infant is within the first 7 days of life and has never been intubated or has received less than 24 hours of total cumulative intubated respiratory support; 2)the infant is within the first 28 days of life, has been managed with intubated respiratory support for 24 hours or more and is a candidate for extubation followed by non-invasive respiratory support. * 4.no known lethal congenital anomaly or genetic syndromes. * 5.signed parental informed consent exclusion criteria: * 1.considered non-viable by clinician (decision not to administer effective therapies) * 2.life-threatening congenital abnormalities including congenital heart disease (excluding patent ductus arteriosis) * 3.infants known to require surgical treatment * 4.abnormalities of the upper and lower airways * 5.neuromuscular disorders * 6.infants who are \>28 days old and continue to require mechanical ventilation with an endotracheal tube

Keywords: rds infant, newborn vitamin a surfactant
hearing aid signal processing comparative study

Conditions: Hearing Loss, Sensorineural

Summary: participants will be fit with each of two hearing instruments in an aba cross-over design. the study will consist of a total of three approximately 10-day home trials with the devices. participants will be asked to provide qualitative feedback to investigators regarding the performance of and their preference for each hearing instrument.


Eligibility criteria:
inclusion criteria: * moderate to severe sensorineural hearing loss * current hearing aid user exclusion criteria: * lack of willingness to wear study devices for approximately one month * inability to travel to study appointments or to complete questionnaires.